Skip to content

Management Team

For more information, please contact us.

For more information, please contact us.

Dan Teleman, CEO

Mr. Teleman joined Atox Bio in 2010. Prior to joining Atox Bio, Mr. Teleman was the co-founder and CEO of PainReform, a specialty pharmaceutical company focused on pain therapeutics. Before founding PainReform in 2007, Mr. Teleman was a senior Business Development officer at Pharmos, a company focused on the R&D of novel CB2 receptor agonists for the treatment of neuropathic and inflammatory pain. Prior to Pharmos, Mr. Teleman held marketing and sales positions at Amgen, working on Enbrel. Dan served as an officer in an Israel Defense Forces R&D unit, holds an MBA from Duke University-Fuqua School of Business and an MSc in Biotechnology from Ben Gurion University.

Wayne M Dankner, MD, Chief Medical Officer

Dr. Dankner joined Atox Bio in November 2014. Prior to joining Atox Bio, Dr Dankner was at PAREXEL International for 14 years and was the Global Therapeutic Area Lead for Infectious Diseases and Pediatrics since 2006.  He served on the faculty at UCSD Medical Center and Children’s Hospital of San Diego for 13 years as an Associate Professor of Clinical Excellence.  Through his tenure at UCSD and PAREXEL he has over 27 years’ experience in clinical trial management and all phases of drug development activities that have included immunomodulatory drugs for sepsis, antivirals, vaccines and different classes of antibiotics and was involved in the approval of gemifloxacin. He has represented multiple pharmaceutical sponsors in the biotechnology sector before US and European regulatory agencies.  He received his MD from NY Medical College and completed his Pediatric residency at Stanford University Medical Center and Infectious Diseases fellowship at UCSD Medical Center under an NIH Training Grant.

Esti Hayun, CFO

Mrs. Hayun joined Atox Bio in September 2014.  Mrs. Hayun brings over 15 years of experience in both publicly traded and private companies. Prior to joining Atox Bio, Mrs. Hayun served as the CFO of Proteologics Ltd. (TASE: PRTL), a drug discovery company focusing on the Ubiquitin system from 2005 to 2013.  Prior to Proteologics, Mrs. Hayun served as a Finance Manager in several companies, including Colbar LifeSiences Ltd., a Medical Device company.

Mrs. Hayun is a certified CPA. She holds a degree in Business Management and Accounting from the College of Management and a L.L.M. in law from Bar Ilan University.

Michele LaRussa, Chief Regulatory Officer

Mrs. LaRussa joined Atox Bio May 2019.  Michele brings over 27 years of pharma industry experience. She was most recently the VP, Head of Regulatory Affairs at Liquidia Technologies, a late stage, publicly traded biotech company based in Raleigh, North Carolina. Prior to that she was SVP, Global Head of Regulatory Affairs and QA for Kala Pharmaceuticals, a publicly traded biotech company based in Boston. Michele has worked at large pharmaceuticals companies including Novartis, Allergan, and GSK. Over her tenure, Michele has led multiple submissions (NDAs and MAAs) and Advisory Committee Meetings.  She holds a B.S. degree in Chemistry from the University of South Florida.

Corinne Zollmann, PhD, Senior VP CMC

Prior to joining Atox Bio in 2014, Dr. Zollmann was Senior Director of Chemistry, Manufacturing and Controls (CMC) at Chiasma. Prior to that, she served for over 20 years in numerous leadership positions at Teva Pharmaceutical’s Global Innovative R&D Division, and most recently, as Director of the CMC Program for Small Molecules. During this period she gained broad experience in global development of innovative pharmaceutical drug products, including CMC management and development, validation, technology transfer,  regulatory strategy and initiatives, and professional CMC project evaluation and due diligence.

She holds a PhD in Electrochemistry from the Tel Aviv University, and an MSc in Analytical Chemistry and BSc Hons in Chemistry from the University of Cape Town in South Africa.

Meir Batito, VP Quality

Mr. Batito joined Atox Bio in 2016 with over 15 years of pharmaceutical experience.  Prior to joining Atox Bio, Mr. Batito served as QA Senior Director at Teva Pharmaceuticals, leading one of the largest ‘site QA’ groups within the Teva network. Previously, he was Director of laboratories for Kamada Inc, where he led the quality control unit from pre-clinical stage to a successful FDA pre-approval inspection. Earlier in his career, Mr. Batito served as R&D researcher for Perrigo Israel Pharmaceuticals.

Mr. Batito holds a B.Sc. in biotechnology engineering from Ben-Gurion University and an MBA from The Open University of Israel.

Elisa Foltz, VP Commercial

Ms. Foltz joined Atox Bio in January 2021 with more than 20 years of sales, marketing, and consulting experience in the pharmaceutical and biotech industries. Prior to joining Atox Bio, she was the VP, US Marketing at BioCryst Pharmaceuticals, a publicly-traded commercial-stage biotech company based in Durham, North Carolina. Ms. Foltz previously served as the Head of Marketing, North America at Ablynx and held multiple commercial positions of increasing responsibility at CSL Behring in the Philadelphia area. Her experience also includes Pfizer and several privately-held companies. During her professional career, Ms. Foltz has successfully led multiple rare disease and specialty product launches. She holds a B.S. degree in Biology from Virginia Tech and an M.B.A. from the University of Maryland, College Park.

Raymond Kaempfer, PhD, Chief Scientist

A molecular biologist, Dr. Kaempfer obtained his PhD at MIT and served on the biology faculty of Harvard University before becoming the Philip Marcus Professor of Molecular Biology and Cancer Research, Faculty of Medicine, The Hebrew University of Jerusalem. He is an elected member of the European Molecular Biology Organization and created the Graduate Program in Biotechnology of the Hebrew University.